UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

Journal of the American Academy of Dermatology, 2017-03, Vol.76 (3), p.405-417

2017

Volltextzugriff (PDF)

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

The Lancet (British edition), 2017-07, Vol.390 (10091), p.276-288

2017

Volltextzugriff (PDF)

Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)

Journal of the American Academy of Dermatology, 2017-08, Vol.77 (2), p.310-317.e1

2017

Volltextzugriff (PDF)

Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics

Journal of the American Academy of Dermatology, 2013-11, Vol.69 (5), p.729-735

2013

Volltextzugriff (PDF)

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study

Journal of the American Academy of Dermatology, 2016-05, Vol.74 (5), p.841-850

2016

Volltextzugriff (PDF)

Short and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data

Journal of the American Academy of Dermatology, 2017-03, Vol.76 (3), p.432-440.e17

2017

Volltextzugriff (PDF)

Clinical meaningfulness of complete skin clearance in psoriasis

Journal of the American Academy of Dermatology, 2016-07, Vol.75 (1), p.77-82.e7

2016

Volltextzugriff (PDF)

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

The Lancet (British edition), 2008-05, Vol.371 (9625), p.1665-1674

2008

Volltextzugriff (PDF)

Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials

Journal of the American Academy of Dermatology, 2012-05, Vol.66 (5), p.742-751

2012

Volltextzugriff (PDF)

Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis

Journal of the American Academy of Dermatology, 2015-09, Vol.73 (3), p.410-419.e6

2015

Volltextzugriff (PDF)

Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: Rationale for dosing recommendations

Journal of the American Academy of Dermatology, 2010-10, Vol.63 (4), p.571-579

2010

Volltextzugriff (PDF)

Integrated safety analysis: Short- and long-term safety profiles of etanercept in patients with psoriasis

Journal of the American Academy of Dermatology, 2012-08, Vol.67 (2), p.245-256

2012

Volltextzugriff (PDF)

Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population

Journal of the American Academy of Dermatology, 2012-02, Vol.66 (2), p.e33-e45

2012

Volltextzugriff (PDF)

Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study

Journal of the American Academy of Dermatology, 2011-04, Vol.64 (4), p.671-681

2011

Volltextzugriff (PDF)

Single-blind, randomized controlled trial evaluating the treatment of facial seborrheic dermatitis with hydrocortisone 1% ointment compared with tacrolimus 0.1% ointment in adults

Journal of the American Academy of Dermatology, 2012-07, Vol.67 (1), p.e11-e15

2012

Volltextzugriff (PDF)

Monitoring biologics for the treatment of psoriasis

Clinics in dermatology, 2008-09, Vol.26 (5), p.515-521

Papp, Kim A., MD

2008

Volltextzugriff (PDF)

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

The Lancet (British edition), 2017-06, Vol.389 (10086), p.2287-2303

2017

Volltextzugriff (PDF)

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

Journal of the American Academy of Dermatology, 2008, Vol.58 (1), p.106-115

2008

Volltextzugriff (PDF)

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

Journal of the American Academy of Dermatology, 2015-07, Vol.73 (1), p.37-49

2015

Volltextzugriff (PDF)

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

The Lancet (British edition), 2015-08, Vol.386 (9993), p.541-551

2015

Volltextzugriff (PDF)

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

The Lancet (British edition), 2008-05, Vol.371 (9625), p.1675-1684

2008

Volltextzugriff (PDF)

Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study

Journal of the American Academy of Dermatology, 2017-06, Vol.76 (6), p.1093-1102

2017

Volltextzugriff (PDF)

Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment

Journal of the American Academy of Dermatology, 2014-12, Vol.71 (6), p.1183-1190.e3

2014

Volltextzugriff (PDF)

The psychosocial impact of hidradenitis suppurativa

Journal of the American Academy of Dermatology, 2015-11, Vol.73 (5), p.S19-S22

2015

Volltextzugriff (PDF)

1 – 25 von 37

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(36)
Tagungsberichte
(1)

Sprache

Englisch
(37)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Humans
(35)
Science & Technology
(34)
Female
(33)
Life Sciences & Biomedicine
(33)
Male
(32)
Adult
(29)
Middle Aged
(29)
Dermatology
(27)
Psoriasis - Drug Therapy
(26)
Psoriasis
(22)
Treatment Outcome
(21)
Double-Blind Method
(20)
Severity Of Illness Index
(20)
Antibodies, Monoclonal - Adverse Effects
(13)
Antibodies, Monoclonal - Therapeutic Use
(12)
Safety
(12)
Biological And Medical Sciences
(11)
Medical Sciences
(11)
Clinical Trials
(10)
General & Internal Medicine
(10)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of The American Academy Of Dermatology
(23)
The Lancet
(10)
Lancet
(2)
American Journal Of Obstetrics And Gynecology
(1)
Clinics In Dermatology
(1)
Ophthalmology
(1)

1 weiteren anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)

Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study

Short and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data

Clinical meaningfulness of complete skin clearance in psoriasis

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials

Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis

Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: Rationale for dosing recommendations

Integrated safety analysis: Short- and long-term safety profiles of etanercept in patients with psoriasis

Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population

Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study

Single-blind, randomized controlled trial evaluating the treatment of facial seborrheic dermatitis with hydrocortisone 1% ointment compared with tacrolimus 0.1% ointment in adults

Monitoring biologics for the treatment of psoriasis

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study

Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment

The psychosocial impact of hidradenitis suppurativa

Suchergebnisse filtern